Peptide merchant account UK: how to take card payments selling peptides

Why mainstream processors ban peptide sellers

Card schemes and mainstream acquirers group research peptides with unlicensed medicines and research chemicals. Their acceptable-use policies prohibit the category outright, so the decision is automatic and not negotiable. You will usually hit it in one of two ways:

• Declined at onboarding once the product catalogue is reviewed.
• Onboarded then terminated, often with a 90 to 180 day hold on your balance, when a manual review or a chargeback flags what you sell.

The second outcome is the dangerous one: it strands your working capital and leaves a record that follows you. Reapplying to the same processor with the same setup does not change the result. The fix is a different rail, not a different application.

The legal line that decides everything

In the UK, research peptides are lawful to sell only as research chemicals or laboratory reagents, labelled not for human consumption. Present them for human use, dosing or injection and they become unlicensed medicines under MHRA enforcement, which is unlawful to sell and uninsurable to process. Acquirers know this, so your compliance is judged on presentation:

• Clear research-use-only, not-for-human-consumption labelling on every product.
• No medical, therapeutic, performance or anti-ageing claims in copy, metadata or ads.
• Age-gating, certificates of analysis and clear returns terms.

Get this right and you are underwritable. Get it wrong and even a specialist acquirer will decline or terminate. See is it legal to sell peptides in the UK for the full position.

Who underwrites peptides in the UK

There is no high-street acquirer for peptides and no single published list, because acceptance is decided case-by-case on your labelling, claims, volume and history. Specialist research-chemical and nutraceutical acquirers underwrite the category instead. As a broker we hold the relationships and approach the underwriter most likely to take your specific profile, disclosing the risk classification upfront so the right one is contacted from the start. See the peptide merchant account vertical guide for what to expect, and the high-risk payment gateway guide for how the gateway and acquirer fit together.

What a peptide merchant account costs

Blended rate

3.5% to 8.0%, profile-dependent (confirmed at underwriting)

Rolling reserve

10% to 20%, held 90 to 180 days

Settlement

Slower than mainstream; reserve released on a rolling schedule

Underwriting focus

Labelling, claims, catalogue, processing history

A clean, claim-free catalogue with proper labelling is underwritten near the lower end. Human-use claims push you to the top of the range or out of the market entirely.

Conditions of approval: what underwriters actually require

Approval for a peptide account is conditional. A specialist acquirer will attach a set of requirements to any offer, and getting these right before you apply is the difference between placement and decline. Requirements vary by acquirer and by jurisdiction, but these are the conditions we see attached most often. Treat it as a pre-application checklist.

• MCC 5999. Peptide catalogues are typically coded as MCC 5999 (miscellaneous and specialty retail), the catch-all applied to novel and research products that acquirers scrutinise closely.
• A cash reserve. Expect a reserve held to support the account, against chargebacks and regulatory risk. It is your money, released on a rolling schedule, so plan cash flow around it.
• Lab testing on every product. A certificate of analysis or equivalent lab test is required for all products, not a sample of the range.
• A visible research-use-only disclaimer. The site must clearly state the products are intended for research purposes only.
• No benefit or marketing claims. No claims indicating potential benefits (fat loss, muscle gain, digestion and the like) are permitted. Such information may appear next to a product only if accompanied by a clear disclaimer that it is provided for education purposes only.
• A mandatory disclaimer in every product description. Underwriters commonly require the wording below on each product page.

Used solely for in vitro experiments and cannot be: used in clinical trials involving humans; administered to humans as part of an experiment or investigation; or supplied to another party for human investigational use.

• No pill-form peptides. Peptides sold in pill form are generally treated as intended for human consumption, and many acquirers will not accept them at all under internal policy. Capsule products can sink an otherwise clean application.
• Semaglutide and GLP-1 handling. If you sell semaglutide, expect to provide a letter confirming compliance with the requirements to sell it, or to remove the products. GLP-1 peptides are prescription-only medicines and sit outside the research-chemical route entirely. See GLP-1 and weight-loss.
• Genuine volume. Underwriters want to see meaningful processing volume; the category is not worth the risk to them for a low-turnover account.

Requirements and fees are confirmed at underwriting and differ by acquirer and jurisdiction. The list above reflects conditions commonly attached to UK peptide approvals; it is guidance, not a guarantee of acceptance.

Adjacent categories we place

If your range stretches beyond peptides, the same specialist route covers the neighbours: SARMs, research chemicals, nootropics and health supplements. Regulated weight-loss is different: GLP-1 and weight-loss clinics and telehealth providers need pharmacy or CQC registration before any acquirer will onboard them.